Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEGF0444A + bevacizumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MEGF0444A (parsatuzumab) + bevacizumab is an investigational combination therapy comprising two monoclonal antibodies: MEGF0444A (also known as parsatuzumab), a humanized IgG1 monoclonal antibody targeting EGFL7, and bevacizumab, an anti-VEGF monoclonal antibody. MEGF0444A blocks the interaction of EGFL7 with endothelial cells, impairing angiogenesis, while bevacizumab neutralizes VEGF-A, inhibiting tumor angiogenesis and growth. This combination has been evaluated in phase II clinical trials for metastatic colorectal cancer and advanced non-squamous non-small cell lung cancer, often in combination with chemotherapy regimens (e.g., mFOLFOX-6 or carboplatin/paclitaxel)[1][2][3][4][5][7].
- Other names
- parsatuzumab + bevacizumab
02
Targets
Beyond the preview
Go deeper on MEGF0444A + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEGF0444A + bevacizumab.